How good is allogeneic transplantation for high-risk patients with AML?

Best Practice & Research. Clinical Haematology
Hans A Messner

Abstract

Patients with acute myeloid leukemia (AML) may differ significantly in their response to therapy and long-term outcome. A number of risk factors have been identified that characterize patients at diagnosis as well as during their clinical course. At diagnosis these parameters include age, cytogenetic configuration, hemopoietic elements, and a previous history of myelodysplasia or cytoreductive therapy for a preexisting malignancy. They are complemented by the response to induction therapy and subsequent treatments as well as by the duration of response. More recently, gene expression profiling of leukemic cells has added a new dimension to simultaneously assess biological risk factors that may ultimately lead to individualization of therapy. This presentation will review data to address the question of whether or not allogeneic transplants are effective in the management of patients with AML presenting with adverse cytogenetics and older age, showing a poor response to induction therapy, and relapsing after achieving a remission.

References

Jul 26, 2002·British Journal of Haematology·Alan K BurnettUNKNOWN Medical Research Council Adult and Paediatric Working Parties
Sep 18, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yves ChalandonDonna E Hogge
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hartmut BertzJürgen Finke
Dec 17, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·H C FungS J Forman
Jan 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.